InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,702.55
(
-0.19%
)
US TECH 100
19,287.60
(
-0.24%
)
Dow Jones
42,063.36
(
0.09%
)
Brent Oil
74.14
(
0.00%
)
Bitcoin
62,751.63
(
-0.99%
)
Post# of 253172
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120476
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 194578

Monday, 10/05/2015 4:11:04 PM

Monday, October 05, 2015 4:11:04 PM

Post# of 253172
ACOR +12% on Ampyra US patent settlement with AGN:

http://www.sec.gov/Archives/edgar/data/1008848/000100884815000044/report_anda-100115.htm

On October 1, 2015, Acorda Therapeutics, Inc. entered into a settlement agreement with Actavis Laboratories FL, Inc. to resolve pending patent litigation brought by the Company against Actavis involving Ampyra (dalfampridine) Extended-Release Tablets. As a result of the settlement agreement, Actavis will be permitted to market a generic version of Ampyra in the United States at a specified date in 2027, or potentially earlier under certain circumstances.

See #msg-117098125 for the meaning of the italicized phrase.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up